RE:RE:After 14 years, GET AN IND SUBMISSION IN TO THE FDA!!....Daiichi is a leading player in Herceptin and BTI signed a collaboration with it nine months ago next week when the collaboration also expires. The payload is undisclosed; but being a leading player in Herceptin is curious. It appears to be a plausible path forward for xB3-001. We should find out, at the latest, what happened to the collaboration in the next MD&A....
Very unlikely IMO. If a collaboration doesn't produce anything and fades away, they typically don't say anything.
The collaboration is ending but the data analysis may be ongoing or only just starting and would take many more months. And if it does eventally lead to a deal, that could take 6+ months to negotiate before we'd hear anything.
(my bolding)